Company intelligence / Profile preview

Precision Biomonitoring

Guelph, Ontario, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Precision Biomonitoring developed rapid, on-site molecular diagnostic solutions using their proprietary TripleLock technology for diverse applications, with a commercial COVID-19 qPCR program and environmental DNA surveillance platforms, but was acquired and business restructured in 2022–2023[2][1].

Therapeutic areas: OtherInfectious Diseases
Modalities: Diagnostic kitqPCRMolecular diagnostic
Industry: Molecular Diagnostics

Partnerships

ams AG (COVID-19 antigen rapid tests partnership)

Beyond the preview

Go deeper on Precision Biomonitoring.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Biomonitoring.

Explore the full profile